



PRODUCT: **BLNREP® (belantamab mafodotin-blmf)**

COMPANY: GlaxoSmithKline

THERAPEUTIC AREA & INDICATION:

Treatment of adults with relapsed
or refractory multiple myeloma

ABOUT THE PRODUCT

Patients with relapsed/refractory multiple myeloma often cycle through different treatments as their cancer progresses and becomes resistant to standard of care. This is why it is important to bring therapies with novel mechanisms of actions such as BLENREP (belantamab mafodotin-blmf) to patients. As the first anti-BCMA therapy approved anywhere in the world, BLENREP is a readily available off-the-shelf treatment administered in an outpatient setting that has significant potential for patients with limited treatment options. With additional studies underway evaluating it in different treatment settings and in combination, BLENREP may further evolve the multiple myeloma treatment paradigm and improve.